Wednesday, December 06, 2017 3:03:34 PM
Cyrcadia is initially targeting the 40% of women who have dense breast tissue. Twenty-eight states now mandate that physicians tell their patients that they have a dense breast condition, therefore a higher propensity for cancer, and that the current diagnostic modalities are challenged with their condition in which the tissue itself can mask cancer cells and lesions. Additionally, Cyrcadia intends to be a supplementary screening solution for those 70 percent of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, representing over 1.2 million biopsies for women on non-cancerous tissue annually.
“It is an honor and privilege to participate in the growth of a product that is truly the only life-changing wearable for women of its kind,” said Antoniacci. “Together, we can positively affect countless women and change the trajectory of my own personal and familial experiences. The ability to help lead that movement is something very special to me.”
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM